1 / 15

Lack of Evidence of a Clopidogrel – Statin Interaction in the CHARISMA Trial

Lack of Evidence of a Clopidogrel – Statin Interaction in the CHARISMA Trial. J Am Coll Cardiol 2007;50:291-5.

oded
Télécharger la présentation

Lack of Evidence of a Clopidogrel – Statin Interaction in the CHARISMA Trial

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Lack of Evidence of a Clopidogrel – Statin Interaction in the CHARISMA Trial J Am Coll Cardiol 2007;50:291-5 Jacqueline Saw, MD*, Danielle Brennan, MS†, Steven Steinhubl, MD‡, Deepak L. Bhatt, MD†, Koon-Hou Mak, MD§, Keith Fox, MB^, and Eric J. Topol, MD#for the CHARISMA Investigators *Vancouver, British Columbia, Canada; †Cleveland, Ohio; ‡Lexington, Kentucky; §Singapore; ^Edinburgh, Scotland, United Kingdom; and #La Jolla, California

  2. Study Objective • To evaluate the potential impact of long-term concomitant administration of clopidogrel and statins in the CHARISMA study on long-term clinical event-rates

  3. CHARISMA Trial Design Median 28 months Bhatt DL, et al. N Eng J Med 2006;354:1-12.

  4. Methods (1) • We performed a secondary analysis evaluating the differential treatment effect (interaction) of clopidogrel versus placebo according to the type of statin administered: • CYP3A4-MET versus Non-CYP3A4-MET • Atorvastatin versus pravastatin • Analyses of the entire CHARISMA cohort, symptomatic cohort, & asymptomatic cohort

  5. Methods (2) • Statin administration was non-randomized • Recorded at baseline and each follow-up visit • Our analysis was based upon baseline statin administered —2 major groups: • CYP3A4-MET: Statins predominantly metabolized by CYP3A4 (atorvastatin, lovastatin, simvastatin) • Non-CYP3A4-MET: Statins not predominantly metabolized by CYP3A4 (pravastatin, fluvastatin)

  6. Statistical Analyses • Intention-to-treat population, 2-sided tests, 5% α • Chi-square to compare baseline variables • Cox proportional-hazards model to estimate the HR and 95% CI for the primary efficacy endpoint • Logistic regression model to compute OR and 95% CI for the primary safety endpoint • Interactions tested with Cox proportional-hazards model, incorporating terms for randomized treatment and treatment-by-statin, to assess if treatment effect differed for CYP3A4-MET vs. non-CYP3A4-MET, and atorvastatin vs. pravastatin • SAS software (8.2, SAS Institute, Cary, NC).

  7. Baseline Characteristics

  8. HR 1.02p=0.87 HR 0.93p=0.23 HR 0.78p=0.19 HR 0.80p=0.06 HR 0.72p=0.13 HR 0.87p=0.08 HR 0.89p=0.18 Primary Efficacy Endpoint

  9. Interaction: CYP3A4-MET The interaction of the type of statin (CYP3A4-MET vs. non-CYP3A4-MET) and randomized treatment was not significant. p=0.69

  10. Interaction: Atorvastatin/Pravastatin The interaction of atorvastatin versus pravastatin and randomized treatment was not significant. p=0.54

  11. p<0.001 Statins Versus No Statins p<0.001

  12. Symptomatic Patients In the symptomatic subgroup, the interaction of the type of statin used (CYP3A4-MET vs. Non-CYP3A4-MET) and the randomized treatment (clopidogrel vs. placebo) remained insignificant: p=0.18 Likewise, the interaction of atorvastatin versus pravastatin and randomized treatment was not significant: p=0.25

  13. OR 1.29p=0.20 OR 1.24p=0.11 OR 1.19p=0.33 OR 1.19p=0.39 OR 1.14p=0.76 OR 0.87p=0.61 OR 1.04p=0.93 GUSTO Major Bleeding

  14. Limitations • Retrospective post hoc analysis • Statin administration not randomized • Statin dose not recorded • Analysis based upon baseline statin use • Platelet aggregation or activation not assessed

  15. Conclusions • Despite theoretical concerns and ex vivo testing suggesting a potential negative interaction with concomitant clopidogrel and CYP3A4-MET statin administration, there was no evidence of an interaction clinically in a large placebo-controlled trial with long-term follow-up • Our study is concordant with other clinical analyses, suggesting that clinicians need not choose statins on the basis of CYP3A4-metabolism, even when long-term clopidogrel co-administration is required

More Related